These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
208 related items for PubMed ID: 22718209
1. Antibiotic resistance of pathogens causing community-acquired pneumonia. Feldman C, Anderson R. Semin Respir Crit Care Med; 2012 Jun; 33(3):232-43. PubMed ID: 22718209 [Abstract] [Full Text] [Related]
2. Controversies in the treatment of pneumococcal community-acquired pneumonia. Feldman C, Anderson R. Future Microbiol; 2006 Oct; 1(3):271-81. PubMed ID: 17661640 [Abstract] [Full Text] [Related]
3. Antibiotics in childhood pneumonia. Hale KA, Isaacs D. Paediatr Respir Rev; 2006 Jun; 7(2):145-51. PubMed ID: 16765302 [Abstract] [Full Text] [Related]
5. Role of gemifloxacin in community-acquired pneumonia. Tillotson GS. Expert Rev Anti Infect Ther; 2008 Aug; 6(4):405-18. PubMed ID: 18662107 [Abstract] [Full Text] [Related]
8. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. Feldman C. J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171 [Abstract] [Full Text] [Related]
9. Clinical experience in the management of community-acquired pneumonia: lessons from the use of fluoroquinolones. Carratalá J, Martín-Herrero JE, Mykietiuk A, García-Rey C. Clin Microbiol Infect; 2006 May; 12 Suppl 3():2-11. PubMed ID: 16669924 [Abstract] [Full Text] [Related]
10. Antimicrobial drug use and resistance among respiratory pathogens in the community. Low DE. Clin Infect Dis; 2001 Sep 15; 33 Suppl 3():S206-13. PubMed ID: 11524720 [Abstract] [Full Text] [Related]
11. The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia. Ferrer M, Menendez R, Amaro R, Torres A. Clin Chest Med; 2011 Sep 15; 32(3):491-505. PubMed ID: 21867818 [Abstract] [Full Text] [Related]
13. [Updated acute community-acquired pneumonia in adults: Guidelines for initial antimicrobial therapy based on local evidence from the South American Working Group (ConsenSur II)]. Bantar C, Curcio D, Jasovich A, Bagnulo H, Arango A, Bavestrello L, Famiglietti A, García P, Lopardo G, Losanovscky M, Martínez E, Pedreira W, Piñeyro L, Remolif C, Rossi F, Varón F. Rev Chilena Infectol; 2010 Jun 15; 27 Suppl 1():S9-S38. PubMed ID: 20737129 [Abstract] [Full Text] [Related]
16. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin. Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS. Int J Antimicrob Agents; 2004 Jun 15; 23(6):533-46. PubMed ID: 15194123 [Abstract] [Full Text] [Related]
17. [Community acquired pneumonia; no reason to revise current Dutch antibiotic guidelines]. Oosterheert JJ, Bonten MJ, Schneider MM, Hoepelman IM. Ned Tijdschr Geneeskd; 2003 Mar 01; 147(9):381-6. PubMed ID: 12661455 [Abstract] [Full Text] [Related]
18. Community-acquired pneumonia in adults: initial antibiotic therapy. King DE, Pippin HJ. Am Fam Physician; 1997 Aug 01; 56(2):544-50. PubMed ID: 9262534 [Abstract] [Full Text] [Related]
19. [New quinolones for the treatment of community-acquired pneumonia--contra]. Egger M. Dtsch Med Wochenschr; 2003 May 09; 128(19):1071. PubMed ID: 12736860 [No Abstract] [Full Text] [Related]